Protagonist Therapeutics, Inc. (PTGX)

Environment story

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with no approved commercial products and minimal direct operational footprint. The company does not disclose Scope 1, Scope 2, or Scope 3 emissions data in available filings. No net-zero targets or environmental commitments are stated. The company does not report renewable energy usage percentages or decarbonization initiatives. No controversies related to environmental violations, toxic waste, water consumption, or habitat damage are disclosed. As a pre-commercial biotech firm with contracted R&D and manufacturing, direct environmental impact is limited; however, absence of environmental reporting prevents granular assessment.

Social story

Protagonist Therapeutics employs 132 full-time equivalent employees as of December 31, 2025 (103 in R&D, 29 in G&A). The company does not disclose CEO-to-median-worker pay ratio, workforce diversity metrics (gender or underrepresented racial/ethnic groups), leadership diversity percentages, or turnover rates in the 10-K filing. No union-related activities, strikes, NLRB complaints, or labor-suppression controversies are reported. The company does not address supply-chain human-rights audits, conflict minerals policies, or fair-labor commitments. No DEI programs, pay-equity audits, or supplier-diversity initiatives are disclosed. The absence of social metrics and initiatives reflects typical pre-commercial biotech transparency gaps.

Governance story

Protagonist Therapeutics does not disclose board composition, independence percentages, or share structure details in the provided 10-K excerpt. The company does not report lobbying expenditures targeting environmental or consumer-protection deregulation. No active antitrust, consumer-safety, SEC enforcement proceedings, or financial-fraud regulatory actions are disclosed in the risk factors or MD&A. The company references consulting and scientific advisory arrangements with healthcare providers structured to comply with anti-kickback and fraud statutes, but no violations or fines are mentioned. No dual-class share structures or supermajority voting arrangements are evident from the filings. Absence of specific governance metrics and controversies limits detailed scoring.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Protagonist Therapeutics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Protagonist Therapeutics, Inc. in the app for interactive charts and portfolio building.

More in Healthcare